New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Friday 05/31/2024 the closing price of the Lexicon Pharmaceuticals Inc share was $1.70 on BTT.Compared to the opening price on Friday 05/31/2024 on BTT of $1.71, this is a drop of 0.59%.Lexicon Pharmaceuticals Inc's market capitalization is $594.27 M by 361.49 M shares outstanding.
Is Lexicon Pharmaceuticals stock a Buy, Sell or Hold?
Lexicon Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 1 hold ratings, and 0 sell ratings.What was the 52-week low for Lexicon Pharmaceuticals stock?
The low in the last 52 weeks of Lexicon Pharmaceuticals stock was 0.92. According to the current price, Lexicon Pharmaceuticals is 185.83% away from the 52-week low.What was the 52-week high for Lexicon Pharmaceuticals stock?
The high in the last 52 weeks of Lexicon Pharmaceuticals stock was 3.73. According to the current price, Lexicon Pharmaceuticals is 45.84% away from the 52-week high.What are analysts forecasts for Lexicon Pharmaceuticals stock?
The 4 analysts offering price forecasts for Lexicon Pharmaceuticals have a median target of 10.25, with a high estimate of 20.00 and a low estimate of 3.00. The median estimate represents a 16.68 difference from the last price of 1.71.Lexicon Pharmaceuticals Stock Snapshot
1.70
Bid
2,201.00
Bid Size
1.72
Ask
6,700.00
Ask Size
5/31/2024
Date
3:59 PM
Time
60,495.00
Volume
1.70
Prev. Close
1.71
Open
594.27 M
Market Cap
361.49 M
Number of Shares
1.69
Day Low
1.75
Day High
1.71
0.92
52 Week Low
3.73
52 Week High
1.71
0.00
Dividend
0.00
Dividend Yield
-1.94
P/E Ratio
95.87
Free Float in %
-0.70
EPS 2024
0.62
Book Value per Share
-0.31
Cash Flow per Share
Lexicon Pharmaceuticals NewsMore News
TipRanks
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
GlobeNewswire
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
GlobeNewswire
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
GlobeNewswire
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Benzinga
Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
Historical Prices for Lexicon Pharmaceuticals
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Lexicon Pharmaceuticals Analyst Data
Total Analysts: 4
Buy Ratings: 3 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 3.00 Median: 10.25 Highest: 20.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Lexicon Pharmaceuticals Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/03/24 | Needham & Company, LLC | Maintained Hold | neutral | |||
| 04/23/24 | Needham & Company, LLC | Maintained Hold | neutral | |||
| 04/11/24 | Needham & Company, LLC | Maintained Hold | neutral | |||
| 05/31/23 | Citigroup Corp. | Maintained Buy | $8 | gut | ||
| 05/30/23 | Needham & Company, LLC | Maintained Hold | neutral | |||
| 03/07/23 | Jefferies & Company Inc. | Maintained Hold | $3 | neutral | ||
| 08/12/22 | Piper Sandler | Maintained Buy | $10 | gut | ||
| 07/01/22 | Citigroup Corp. | Maintained Buy | $20 | gut |
Lexicon Pharmaceuticals Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 24 | 84 | 159 | 350 | 533 |
| Dividend | 0.00 | 0.00 | 0.00 | - | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | - | - |
| EPS | -0.70 | -0.64 | -0.43 | 0.14 | 0.63 |
| P/E Ratio | -2.41 | -2.67 | -3.94 | 12.44 | 2.70 |
| EBIT | -194 | -193 | -143 | 41 | 190 |
| EBITDA | -201 | -136 | -101 | - | - |
| Net Profit | -200 | -201 | -148 | 43 | 191 |
| Net Profit Adjusted | -217 | -166 | -126 | - | - |
| Pre-Tax Profit | -200 | -201 | -148 | 43 | 191 |
| Net Profit (Adjusted) | -206 | -264 | -299 | - | - |
| EPS (Non-GAAP) ex. SOE | -0.35 | 0.36 | - | - | - |
| EPS (GAAP) | -0.70 | -0.64 | -0.43 | 0.14 | 0.63 |
| Gross Income | 27 | 84 | 180 | 332 | 490 |
| Cash Flow from Investing | -1 | -1 | -1 | -1 | - |
| Cash Flow from Operations | -158 | -195 | -97 | 45 | - |
| Cash Flow from Financing | 235 | 159 | 140 | -69 | - |
| Cash Flow per Share | -0.31 | - | - | - | - |
| Free Cash Flow | 0 | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 0.62 | - | - | - | - |
| Net Debt | -52 | -108 | - | - | - |
| Research & Development Exp. | 73 | 99 | 106 | 88 | 97 |
| Capital Expenditure | 1 | 1 | 1 | 1 | - |
| Selling, General & Admin. Exp. | 143 | 184 | 204 | 203 | 203 |
| Shareholder’s Equity | 139 | 91 | 191 | 244 | - |
| Total Assets | 262 | 233 | 284 | 275 | - |
| Previous Quarter ending 03/31/24 | Current Quarter ending 06/30/24 | Next Quarter ending 09/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 4 | 5 | 5 | 5 | 5 |
| Average Estimate | -0.180 USD | -0.176 USD | -0.173 USD | -0.705 USD | -0.636 USD |
| Year Ago | -0.170 USD | -0.220 USD | -0.210 USD | -0.790 USD | -0.705 USD |
| Publish Date | 5/2/2024 | 8/1/2024 | 11/6/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 4 | 5 | 5 | 5 | 5 |
| Average Estimate | 1 USD | 3 USD | 8 USD | 24 USD | 84 USD |
| Year Ago | 0 USD | 0 USD | 0 USD | 1 USD | 24 USD |
| Publish Date | 5/2/2024 | 8/1/2024 | 11/6/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales | 90 | 63 | 322 | 24 | 0 | 0 | 1 |
| Change of sales in % | 8.40 | -30.03 | 409.54 | -92.55 | -98.76 | -53.36 | 766.19 |
| Gross profit on sales | 87 | 59 | 317 | 20 | - | 0 | 1 |
| Gross profit on sales change in % | - | -32.01 | 438.77 | -93.59 | - | - | - |
| Operating income | -135 | -103 | 170 | -173 | -87 | -101 | -172 |
| Operating income change in % | 2.38 | 23.26 | - | - | 49.74 | -15.70 | -70.45 |
| Income before tax | -142 | -121 | 124 | -59 | -88 | -102 | -177 |
| Income before tax change in % | -0.20 | 14.93 | - | - | -49.82 | -16.16 | -73.74 |
| Income after tax | -129 | -121 | 130 | -59 | -88 | -102 | -177 |
| Income after tax change in % | 8.75 | 6.59 | - | - | -49.82 | -16.16 | -73.74 |
Balance Sheet
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 389 | 315 | 305 | 47 | 23 | 77 | 136 |
| Total liabilities change in % | 2.51 | 2.63 | 2.25 | 0.00 | 0.01 | 0.29 | 0.43 |
| Equity | 52 | -26 | 117 | 156 | 114 | 117 | 93 |
| Equity change in % | -66.90 | -150.68 | - | 33.54 | -27.36 | 3.11 | -20.50 |
| Balance sheet total | 441 | 289 | 422 | 204 | 137 | 194 | 229 |
| Balance sheet total change in % | -53.24 | -34.61 | 46.15 | -51.69 | -32.82 | 41.92 | 18.08 |
Key Data
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 0.86 | 0.60 | 2.76 | 0.22 | 0.00 | 0.00 | 0.01 |
| P/E ratio (year end quote, basic EPS) | - | - | 3.72 | - | - | - | - |
| P/E ratio (ear end quote, diluted EPS) | - | - | 3.72 | - | - | - | - |
| P/E ratio (year end quote) | - | - | 3.72 | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 11.80 | -9.15 | 27.76 | 76.73 | 82.97 | 60.28 | 40.58 |
| Debt ratio in % | 88.20 | 109.15 | 72.24 | 23.27 | 17.03 | 39.72 | 59.42 |
Lexicon Pharmaceuticals Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 05/09/2024 | 57,546,100.00 | 136,180,481.00 | n/a | Buy | No |
| DEBBANE RAYMOND | 04/27/2024 | 8,032.00 | 1,348,879.00 | n/a | Buy | No |
| BARKER SAM L | 04/27/2024 | 8,032.00 | 87,649.00 | n/a | Buy | No |
| Swain Judith L | 04/27/2024 | 8,032.00 | 48,364.00 | n/a | Buy | No |
| LEFKOWITZ ROBERT J MD | 04/27/2024 | 8,032.00 | 48,364.00 | n/a | Buy | No |
| Amouyal Philippe | 04/27/2024 | 8,032.00 | 248,364.00 | n/a | Buy | No |
| SOBECKI CHRISTOPHER J | 04/27/2024 | 8,032.00 | 167,055.00 | n/a | Buy | No |
| Invus Public Equities, L.P. | 03/12/2024 | 1,150,922.00 | 1,150,922.00 | 108.50 | Buy | No |
| McDermott Wendy | 02/27/2024 | 22,425.00 | 52,694.00 | 2.62 | Sell | No |
| Granowitz Craig B | 02/27/2024 | 31,265.00 | 47,626.00 | 2.62 | Sell | No |
| Alexander Kristen | 02/27/2024 | 11,793.00 | 47,800.00 | 2.62 | Sell | No |
| COATS LONNEL | 02/27/2024 | 61,371.00 | 1,098,068.00 | 2.62 | Sell | No |
| Kassler-Taub Kenneth B. | 02/27/2024 | 24,353.00 | 162,672.00 | 2.62 | Sell | No |
| Crum Brian T | 02/27/2024 | 25,604.00 | 177,497.00 | 2.62 | Sell | No |
| MAIN ALAN J | 02/27/2024 | 24,408.00 | 255,724.00 | 2.62 | Sell | No |
| WADE JEFFREY L | 02/27/2024 | 37,691.00 | 324,214.00 | 2.62 | Sell | No |
| McDermott Wendy | 02/27/2024 | 18,944.00 | 47,422.00 | n/a | Buy | No |
| McDermott Wendy | 02/27/2024 | 27,697.00 | 75,119.00 | n/a | Buy | No |
| Granowitz Craig B | 02/27/2024 | 27,916.00 | 43,101.00 | n/a | Buy | No |
| Alexander Kristen | 02/27/2024 | 2,700.00 | 33,050.00 | n/a | Buy | No |
| Alexander Kristen | 02/27/2024 | 15,927.00 | 59,593.00 | n/a | Buy | No |
| Alexander Kristen | 02/27/2024 | 10,616.00 | 43,666.00 | n/a | Buy | No |
| Granowitz Craig B | 02/27/2024 | 35,790.00 | 78,891.00 | n/a | Buy | No |
| COATS LONNEL | 02/27/2024 | 91,364.00 | 1,039,056.00 | n/a | Buy | No |
| COATS LONNEL | 02/27/2024 | 120,383.00 | 1,159,439.00 | n/a | Buy | No |
Lexicon Pharmaceuticals Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2022 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2021 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2020 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2019 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2018 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2017 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2016 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2015 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2014 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2013 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2012 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2011 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2010 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
| 2009 | Lexicon Pharmaceuticals Inc | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Lexicon Pharmaceuticals Inc Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.176 USD | Q2 2024 Earnings Release | 08/01/2024 |
| Earnings Report | -0.173 USD | Q3 2024 Earnings Release | 11/06/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 03/12/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 05/01/2025 |
Lexicon Pharmaceuticals Inc Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/10/2024 |
| Earnings Report | -0.200 USD | Q1 2024 Earnings Release | 05/02/2024 |
| Earnings Report | -0.200 USD | Q4 2023 Earnings Release | 03/11/2024 |
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Lexicon Pharmaceuticals Shareholder
| Owner | in % |
|---|---|
| Freefloat | 95.87 |
| Artal Group SA | 47.74 |
| Fidelity Management & Research Co. LLC | 3.46 |
| Vanguard Group, Inc. (Subfiler) | 2.55 |
| Fidelity Management Trust Co. | 2.18 |
| Fidelity Growth Company Fund | 1.62 |
| Vanguard Total Stock Market ETF | 1.58 |
| BlackRock Fund Advisors | 1.46 |
| OrbiMed Advisors LLC | 1.44 |
| OrbiMed Advisors Private Equity | 1.44 |
| BlackRock Institutional Trust Co. NA | 1.38 |
| JPMorgan Investment Management, Inc. | 1.11 |
| Geode Capital Management LLC | 0.97 |
| NEA Management Co. LLC | 0.97 |
| NEA Management Co. | 0.97 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
